PRECIGEN, INC. Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest
PRECIGEN, INC. (PGEN) had Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest of $71.71 million as of 2019-12-31, per its 10-K filed 2022-03-01.
Discontinued › Balance Sheet › Equity, Including Portion Attributable to Noncontrolling Interest
us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest · last filed 2022-03-01
- 2019-12-31: Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest $71.71M.
- 2019-09-30: Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest $228.42M.
- 2019-06-30: Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest $279.22M.
- 2019-03-31: Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest $334.82M.
| Period end | Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest | Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest as first filed |
|---|---|---|
| 2019-12-31 | $71.71M 10-K · filed 2022-03-01 | |
| 2019-09-30 | $228.42M 10-Q · filed 2020-11-09 | |
| 2019-06-30 | $279.22M 10-Q · filed 2020-08-10 | |
| 2019-03-31 | $334.82M 10-Q · filed 2020-08-10 | |
| 2018-12-31 | $378.72M 10-K · filed 2022-03-01 | |
| 2018-09-30 | $555.44M 10-Q · filed 2019-11-12 | |
| 2018-06-30 | $567.14M 10-Q · filed 2019-11-12 | |
| 2018-03-31 | $634.12M 10-Q · filed 2019-08-09 | $571.43M 10-Q · filed 2018-05-10 |
| 2017-12-31 | $546.54M 10-K · filed 2021-03-01 | |
| 2017-09-30 | $553.18M 10-Q · filed 2017-11-09 | |
| 2017-06-30 | $571.55M 10-Q · filed 2017-08-09 | |
| 2017-03-31 | $550.16M 10-Q · filed 2017-05-10 | |
| 2016-12-31 | $569.25M 10-K · filed 2020-03-02 | |
| 2016-09-30 | $608.42M 10-Q · filed 2016-11-09 | |
| 2016-06-30 | $628.18M 10-Q · filed 2016-08-09 | |
| 2016-03-31 | $674.83M 10-Q · filed 2016-05-10 | |
| 2015-12-31 | $704.89M 10-K · filed 2019-03-01 | |
| 2015-09-30 | $729.62M 10-Q · filed 2015-11-09 | |
| 2015-06-30 | $486.93M 10-Q · filed 2015-08-10 | |
| 2015-03-31 | $653.35M 10-Q · filed 2015-05-11 | |
| 2014-12-31 | $409.29M 10-K · filed 2018-03-01 | |
| 2014-09-30 | $379.84M 10-Q · filed 2014-11-13 | |
| 2014-06-30 | $388.37M 10-Q · filed 2014-08-14 | |
| 2014-03-31 | $431.90M 10-Q · filed 2014-05-09 | |
| 2013-12-31 | $381.34M 10-K · filed 2017-03-01 | |
| 2013-09-30 | $391.21M 10-Q · filed 2013-11-07 | |
| 2013-06-30 | -$361.52M 10-Q/A · filed 2013-10-21 | |
| 2012-12-31 | -$321.55M 10-K · filed 2016-02-29 | |
| 2011-12-31 | -$221.26M 10-K · filed 2015-03-02 | |
| 2010-12-31 | -$127.73M 10-K · filed 2014-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NewAmsterdam Pharma Co N.V. (NAMS) | $2.719B | -15.37 | |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |